The Cocoon® Platform Combined With The 4D-Nucleofector® LV Unit: A Non-Viral Workflow For Modifying Primary T Cells

By Boon Hwa Neo, Samatha Bandapalle, Joseph O’Connor, Kelly Lin, Kalyani Daita, Janet Sei, Meike Zander, Timo Gleissner, Jenny Schroeder, Eytan Abraham, Yaling Shi

The integration of the Cocoon® Platform and 4D-Nucleofector® LV Unit offers a promising solution for automating non-viral cell therapy manufacturing. By pre-transfecting PBMCs, this combined approach delivers gene-modified T cells with clinically relevant attributes, including high yield, efficiency, and purity.

This non-viral gene delivery system eliminates the need for costly and time-consuming viral vector preparation. The integrated platform provides scalability, enhanced process control, and reduced operational costs, ultimately leading to the production of high-quality cell immunotherapies.

Future studies will explore the use of a stable expression system to deliver CAR-coding plasmids, further advancing the potential of this technology for cell therapy applications.